サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1147908

気管支炎治療薬の世界市場

Bronchitis Treatments: Global Markets
出版日: | 発行: BCC Research | ページ情報: 英文 98 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
気管支炎治療薬の世界市場
出版日: 2022年11月03日
発行: BCC Research
ページ情報: 英文 98 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の気管支炎治療薬の市場規模は、2022年の58億米ドルから、2027年には69億米ドルに成長し、2022年から2027年のCAGRは3.5％と予測されています。

急性気管支炎の部門は、2022年の24億米ドルから、2027年には28億米ドルに成長し、予測期間中のCAGRは3.7%と推定されています。また、慢性気管支炎の部門は、2022年の34億米ドルから、2027年には40億米ドルに成長し、予測期間中のCAGRは3.3％と推定されています。

当レポートでは、世界の気管支炎治療薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 概要

第4章 市場力学

  • 市場影響要因
  • 市場促進要因
  • 市場抑制要因

第5章 COVID-19の影響

  • COVID-19の進行
  • 疫学

第6章 世界の気管支炎治療薬市場：タイプ別

  • 世界の気管支炎治療薬市場：タイプ別
  • 急性気管支炎
  • 慢性気管支炎

第7章 世界の気管支炎治療薬市場：薬剤クラス別

  • 気管支拡張薬
  • 抗生物質
  • 抗炎症剤

第8章 世界の気管支炎治療薬市場：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第9章 企業プロファイル

  • ASTRAZENECA
  • BAYER AG
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • CIPLA INC.
  • DR. REDDY'S LABORATORIES LTD.
  • GLAXOSMITHKLINE PLC
  • MERCK & CO. INC.
  • NOVARTIS AG
  • PFIZER INC.
  • SANOFI
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
図表

List of Tables

  • Summary Table A : Global Market for Bronchitis Treatments, Through 2027
  • Summary Table B : Global Market for Bronchitis Treatments, by Type, Through 2027
  • Summary Table C : Global Market for Bronchitis Treatments, by Drug Class, Through 2027
  • Table 1 : AstraZeneca Pipeline Drugs, 2022
  • Table 2 : COVID-19 Confirmed Cases and Deaths, by WHO Region, as of June 15, 2022
  • Table 3 : Global Market for Bronchitis Treatments, Through 2027
  • Table 4 : Global Market for Bronchitis Treatments, by Type, Through 2027
  • Table 5 : Global Market for Bronchitis Treatments, by Region, Through 2027
  • Table 6 : Global Market for Acute Bronchitis Treatments, Through 2027
  • Table 7 : Global Market for Chronic Bronchitis Treatments, Through 2027
  • Table 8 : Global Market for Bronchitis Treatments, by Drug Class, Through 2027
  • Table 9 : Global Market for Bronchodilators for Bronchitis Treatment, Through 2027
  • Table 10 : Global Market for Antibiotics for Bronchitis Treatment, by, Through 2027
  • Table 11 : Global Market for Anti-inflammatories for Bronchitis Treatment, Through 2027
  • Table 12 : Global Market for Bronchitis Treatments, by Region, Through 2027
  • Table 13 : North American Market for Bronchitis Treatments, by Country, Through 2027
  • Table 14 : European Market for Bronchitis Treatments, by Country, Through 2027
  • Table 15 : Asia-Pacific Market for Bronchitis Treatments, by Country, Through 2027
  • Table 16 : South American Market for Bronchitis Treatments, Through 2027
  • Table 17 : Middle East and African Market for Bronchitis Treatments, Through 2027
  • Table 18 : AstraZeneca: Financial Performance, 2018-2021
  • Table 19 : Bayer AG: Marketed Products
  • Table 20 : Bayer AG: Net Revenue, 2016-2021
  • Table 21 : Cipla's Key Financials 2021 and 2022
  • Table 22 : Dr. Reddy's Key Financials 2021
  • Table 23 : GlaxoSmithKline: Product Segment
  • Table 24 : GlaxoSmithKline: Key Financials 2021
  • Table 25 : GlaxoSmithKline plc: Recent Developments
  • Table 26 : Merck & Co. Inc.: Business Segment
  • Table 27 : Merck & Co. Inc.: Financial Performance, 2018-2021
  • Table 28 : Novartis Key Financials, 2021
  • Table 29 : Novartis AG: Key Developments
  • Table 30 : Pfizer: Business Segment
  • Table 31 : Pfizer Inc. Revenue, 2021
  • Table 32 : Sanofi: Business Segment
  • Table 33 : Sanofi: Financial Performance, 2021
  • Table 34 : Sun Pharmaceutical: Key Financials 2021
  • Table 35 : Teva Pharmaceutical Industries Key Financials 2021

List of Figures

  • Summary Figure A : Global Market for Bronchitis Treatments, 2020-2027
  • Summary Figure B : Global Market for Bronchitis Treatments, by Type, 2020-2027
  • Summary Figure C : Global Market for Bronchitis Treatments, by Drug Class, 2020-2027
  • Figure 1 : Global Market for Bronchitis Treatments, by Type, 2020-2027
  • Figure 2 : Global Market Shares of Bronchitis Treatments, by Type, 2021
  • Figure 3 : Global Market for Bronchitis Treatments, by Region, 2020-2027
  • Figure 4 : Global Market for Treatments for Acute Bronchitis, 2020-2027
  • Figure 5 : Global Market for Chronic Bronchitis Treatments, 2020-2027
  • Figure 6 : Global Market for Bronchitis Treatments, by Drug Class, 2020-2027
  • Figure 7 : Global Market for Bronchitis Treatments, by Drug Class, 2021
  • Figure 8 : Global Market for Bronchodilators for Bronchitis Treatment, 2020-2027
  • Figure 9 : Global Market for Antibiotics for Bronchitis Treatment, 2020-2027
  • Figure 10 : Global Market for Anti-inflammatories for Bronchitis Treatment, 2020-2027
  • Figure 11 : Global Market for Bronchitis Treatments, by Region, 2020-2027
  • Figure 12 : Global Market Shares of Bronchitis Treatments, by Region, 2021
  • Figure 13 : North American Market for Bronchitis Treatments, by Country 2020-2027
  • Figure 14 : U.S. Market for Bronchitis Treatments, 2020-2027
  • Figure 15 : Canadian Market for Bronchitis Treatments, 2020-2027
  • Figure 16 : Mexican Market for Bronchitis Treatments, 2020-2027
  • Figure 17 : European Market for Bronchitis Treatments, by Country, 2020-2027
  • Figure 18 : U.K. Market for Bronchitis Treatments, 2020-2027
  • Figure 19 : German Market for Bronchitis Treatments, 2020-2027
  • Figure 20 : French Market for Bronchitis Treatments, 2020-2027
  • Figure 21 : Rest of the European Market for Bronchitis Treatments, 2020-2027
  • Figure 22 : Asia-Pacific Market for Bronchitis Treatments, by Country, 2020-2027
  • Figure 23 : Chinese Market for Bronchitis Treatments, 2020-2027
  • Figure 24 : Japanese Market for Bronchitis Treatments, 2020-2027
  • Figure 25 : Indian Market for Bronchitis Treatments, 2020-2027
  • Figure 26 : South Korean Market for Bronchitis Treatments, 2020-2027
  • Figure 27 : Rest of APAC Market for Bronchitis Treatments, 2020-2027
  • Figure 28 : South American Market for Bronchitis Treatments, 2020-2027
  • Figure 29 : Middle East and African Market for Bronchitis Treatments, 2020-2027
  • Figure 30 : AstraZeneca: Sales Share, by Segment, 2021
  • Figure 31 : AstraZeneca: Revenue Share, by Region, 2021
  • Figure 32 : Bayer AG: Revenue Share, by Region, 2021
  • Figure 33 : Bayer AG: Revenue Share, by Business Segment, 2021
  • Figure 34 : Boehringer Ingelheim: Annual Revenue, 2021
  • Figure 35 : Boehringer Ingelheim: Revenue Share, by Business Segment, 2021
  • Figure 36 : Boehringer Ingelheim: Revenue Share, by Region, 2021
  • Figure 37 : Dr. Reddy's: Revenue Share, by Business Segment, 2021
  • Figure 38 : GlaxoSmithKline plc: Net Revenue, 2016-2020
  • Figure 39 : GlaxoSmithKline plc: Revenue Share, by Business Segment, 2021
  • Figure 40 : GlaxoSmithKline plc: Revenue Share, by Region, 2021
  • Figure 41 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2021
  • Figure 42 : Merck & Co. Inc.: Revenue Share, by Region, 2021
  • Figure 43 : Novartis: Revenue Share, by Business Segment, 2021
  • Figure 44 : Novartis: Total Revenue Share, by Region, 2021
  • Figure 45 : Pfizer Inc.: Revenue Share, by Region, 2021
  • Figure 46 : Pfizer Inc.: Revenue Share, by Business Segment, 2021
  • Figure 47 : Sanofi: Net Sales Share, by Business Segment, 2021
  • Figure 48 : Sanofi: Net Sales Share, by Region, 2021
  • Figure 49 : Sun Pharmaceutical: Revenue Share, by Business Segment, 2021
  • Figure 50 : Sun Pharmaceutical: Total Revenue Share, by Region, 2021
  • Figure 51 : Teva: Annual Revenue, 2018-2020
  • Figure 52 : Teva Pharmaceutical Industries: Revenue Share, by Business Segment, 2021
  • Figure 53 : Teva Pharmaceutical Industries: Total Revenue Share, by Region, 2021
目次
Product Code: PHM266A

Highlights:

The global market for bronchitis treatments is estimated to grow from $5.8 billion in 2022 to $6.9 billion in 2027, with a compound annual growth rate (CAGR) of 3.5% for the period of 2022-2027.

The global market for Acute bronchitis treatments is estimated to grow from $2.4 billion in 2022 to $2.8 billion in 2027, with a CAGR of 3.7% for the period of 2022-2027.

The global market for Chronic bronchitis treatments is estimated to grow from $3.4 billion in 2022 to $4.0 billion in 2027, with a CAGR of 3.3% for the period of 2022-2027.

Report Scope:

This study offers a global view of the treatment options for bronchitis in the market. This report analyzes and assesses the types of bronchitis, such as acute and chronic. It also provides information regarding different drugs classes, including antibiotics, anti-inflammatories and bronchodilators.

BCC Research analyzes and makes projections for each market and its segmentation, the regulatory environment, pipeline drugs and future aspects. The report also includes the impact of COVID-19 and profiles of leading companies in the bronchitis treatment market, including AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Cipla Inc., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.

The report covers the major markets of North America and Europe, as well as emerging markets, such as India, China, Japan and South Korea.

Report Includes:

  • 35 total tables
  • An overview of the global markets for the treatment options for bronchitis
  • Analyses of the global market trends, with market revenue data and sales figures for 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the present and future strategies of the companies in the development of drugs and related treatment options for bronchitis, and areas of focus to forecast this market into various segments and sub-segments
  • Estimation of the actual market size for bronchitis treatment, and corresponding market share analysis on the basis of disease type, drug class, treatment options, and geographic region
  • Updated information on key market drivers and opportunities, industry shifts and regulations, and other demographic factors that will influence this market demand in the coming years (2022-2027)
  • Insight into the patent grants and intellectual property aspects of the bronchitis treatment marketplace
  • Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
  • Descriptive company profiles of the leading pharmaceutical players, including AstraZeneca, Bayer AG, Cipla Inc., Sanofi and Pfizer Inc.

Table of Contents

Chapter 1 Introduction

  • 1.1 Study Goals and Objectives
  • 1.2 Reasons for Doing This Study
  • 1.3 Scope of the Report
  • 1.4 Methodology
  • 1.5 Geographic Breakdown
  • 1.6 Analyst's Credentials
  • 1.7 BCC Custom Research
  • 1.8 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

  • 3.1 Introduction
    • 3.1.1 Disease Overview
    • 3.1.2 Bronchitis Types
    • 3.1.3 Pipeline Drugs

Chapter 4 Market Dynamics

  • 4.1 Factors Affecting the Market for Bronchitis Treatments
  • 4.2 Market Drivers
    • 4.2.1 Increase in the Smokers
    • 4.2.2 Growing Geriatric Population
    • 4.2.3 Rise in Chronic Obstructive Pulmonary Disorder Patients
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations

Chapter 5 Impact of COVID-19

  • 5.1 COVID-19 Progression
  • 5.2 Epidemiology
    • 5.2.1 Collaboration Between Organizations and Governments
    • 5.2.2 Spread of Disease

Chapter 6 Global Market for Bronchitis Treatments by Type

  • 6.1 Global Market for Bronchitis Treatments by Type
  • 6.2 Acute Bronchitis
  • 6.3 Chronic Bronchitis

Chapter 7 Global Market for Bronchitis Treatments by Drug Class

  • 7.1 Bronchodilators
  • 7.2 Antibiotics
  • 7.3 Anti-inflammatories

Chapter 8 Global Market for Bronchitis Treatments by Region

  • 8.1 North America
    • 8.1.1 U.S.
    • 8.1.2 Canada
    • 8.1.3 Mexico
  • 8.2 Europe
    • 8.2.1 U.K.
    • 8.2.2 Germany
    • 8.2.3 France
    • 8.2.4 Rest of Europe
  • 8.3 Asia-Pacific
    • 8.3.1 China
    • 8.3.2 Japan
    • 8.3.3 India
    • 8.3.4 South Korea
    • 8.3.5 Rest of Asia-Pacific
  • 8.4 South America
  • 8.5 Middle East and Africa

Chapter 9 Company Profiles

  • ASTRAZENECA
  • BAYER AG
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • CIPLA INC.
  • DR. REDDY'S LABORATORIES LTD.
  • GLAXOSMITHKLINE PLC
  • MERCK & CO. INC.
  • NOVARTIS AG
  • PFIZER INC.
  • SANOFI
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.